Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, driven by the integration of the Biosciences and Diagnostic Solutions (BDS) business. Revenue reached $1,645M, exceeding the $1,623M mean estimate, with legacy Waters revenue up 7% YoY. Despite a GAAP net loss due to $399M in acquisition-related charges, normalized EPS of $3.0076 was effectively in-line with the $3.01 consensus. Significant restructuring actions were initiated to achieve $120M in annual savings to offset increased financing costs from the $3.5B debt issuance.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Waters(WAT) the Revenue is 1.645 B (+113.3%), Beat estimate;the EBIT is 411 M (+82.97%), Beat estimate;the EPS is -1.39 (-156.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
1.65B113.27%
1.62B110.36%
+0.02B2.91%
EBITExceed expectations
0.41B82.97%
0.40B79.76%
+0.01B3.21%
EPSMiss expectations
-1.39156.28%
2.5553.44%
-3.9450159.72%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf